Funding to accelerate commercialization of Re-Q and expand pipeline built on breakthrough science targeting the biology of skin aging

加速Re-Q商业化并扩大基于突破性科学的研发管线，靶向皮肤衰老生物学的资金支持

CARLSBAD, Calif.

加利福尼亚州卡尔斯巴德

,

，

June 23, 2026

2026年6月23日

/PRNewswire/ -- Rapalogix Health, a biotechnology company pioneering a new category of longevity-based skin health, today announced the successful closing of a $20 million Series A financing round co-led by Woodline Partners and GordonMD Global Investments LP. The proceeds will support the rapid commercial expansion of .

/美通社/ -- 专注于开创基于长寿理念的皮肤健康新品类的生物技术公司 Rapalogix Health 今日宣布，成功完成由 Woodline Partners 和 GordonMD Global Investments LP 联合领投的2000万美元A轮融资。所筹资金将用于支持其快速商业扩张。

Re-Q

Re-Q

Health

健康

™ (Re-Q)

™（Re-Q）

, the company's professional skincare line, while advancing a pipeline of next-generation products designed to address the underlying biological mechanisms of skin aging.

，该公司的专业护肤系列，同时推进旨在解决皮肤老化根本生物机制的下一代产品管线。

Continue Reading

继续阅读

Founded by skin longevity scientist Rahul Mehta, PhD, renowned dermatologist Doris Day, MD, and leading healthcare executive Brent Saunders, Rapalogix was created with a simple but ambitious vision: to translate advances in longevity science into products that help people maintain healthier, more resilient skin..

Rapalogix 由皮肤长寿科学博士 Rahul Mehta、著名皮肤科医生 Doris Day 医学博士以及领先医疗保健高管 Brent Saunders 共同创立，秉持着一个简单而宏大的愿景：将长寿科学的最新进展转化为帮助人们维持更健康、更具韧性的肌肤的产品。

Rapalogix Health raises $20M Series A to advance longevity-based skin health and expand Re-Q nationally.

Rapalogix Health 完成 2000 万美元 A 轮融资，以推进基于长寿理念的皮肤健康业务，并在全国范围内扩展 Re-Q 品牌。

Post this

发布此内容

While most skincare products target the visible signs of aging, Rapalogix is focused on the biology that drives aging itself. The company's scientific platform is built around TORC1, one of the most extensively studied cellular pathways associated with aging and age-related decline.

当大多数护肤产品针对的是衰老的可见迹象时，Rapalogix 专注于驱动衰老本身的生物学机制。该公司的科学平台围绕 TORC1 构建，这是与衰老及年龄相关衰退最为广泛研究的细胞通路之一。

'This financing marks a significant milestone for Rapalogix and reflects the strength of the science underlying our platform,' said Dr. Mehta, CEO of Rapalogix Health. 'We're building toward a future where skin health and longevity are addressed at the cellular level, and this capital enables us to bring that vision to more patients and physicians across the country while advancing our next generation of therapeutics.

Rapalogix Health 首席执行官梅塔博士表示：“此次融资标志着 Rapalogix 的一个重要里程碑，也彰显了我们平台背后科学基础的雄厚实力。我们正致力于构建一个从细胞层面解决皮肤健康与长寿问题的未来，而这笔资金将使我们能够把这一愿景带给全国更多的患者和医生，同时推动我们下一代疗法的研发进程。”

Our growth strategy puts our premier dermatology physician partners at the forefront, as we collaborate directly with them to drive clinical innovation and advance longevity science in dermatology.'.

我们的增长战略将顶尖的皮肤科医生合作伙伴置于核心位置，通过与他们直接合作，推动临床创新，促进皮肤科长寿科学的发展。

Rapalogix's lead product, Pro-Longevity Face Serum, from its professional skincare line, Re-Q, is based on the company's proprietary approach to selectively modulating TORC1 activity in skin cells. This approach builds on Cambrian Bio's TORnado platform, which solved a longstanding challenge in achieving selective TORC1 modulation, and Rapalogix was spun out to apply this breakthrough to skin health.

Rapalogix 的核心产品是源自其专业护肤系列 Re-Q 的 Pro-Longevity 面部精华液，该产品基于公司独有的选择性调节皮肤细胞中 TORC1 活性的方法。这一方法建立在 Cambrian Bio 的 TORnado 平台之上，该平台解决了长期存在的选择性调节 TORC1 活性的难题，而 Rapalogix 则是为将这一突破应用于皮肤健康而分拆成立的公司。

By selectively supporting key cellular processes associated with skin function and resilience, the company believes it can help establish an entirely new approach to healthy skin aging..

该公司认为，通过选择性支持与皮肤功能和弹性相关的关键细胞过程，可以帮助建立一种全新的健康皮肤老化方法。

Series A financing will support:

A轮融资将用于支持：

Rapid expansion of commercial activities for Re-Q

Re-Q 商业活动的快速扩张

Continued investment in clinical and translational research

持续投入临床与转化研究

Development of additional products targeting skin longevity, hair health and other age-related changes in skin biology

开发针对皮肤长寿、头发健康以及皮肤生物学中其他与年龄相关变化的附加产品

Expansion of scientific, medical and commercial capabilities

科学、医疗和商业能力的扩展

'For years, dermatology has largely focused on treating the visible manifestations of aging,' commented Dr. Day. 'What excites me about Rapalogix is its focus on the biology that drives skin aging. Advances in longevity science are creating opportunities to rethink how we support skin health, and we believe we're only beginning to unlock that potential.'.

“多年来，皮肤科主要侧重于治疗衰老的可见表现，”Day博士评论道，“Rapalogix令我振奋之处在于，它聚焦于驱动皮肤衰老的生物学机制。长寿科学的进步正在创造重新思考我们如何支持皮肤健康的机会，我们相信，我们才刚刚开始释放这一潜力。”

'We're still in the early innings of understanding how longevity science can transform human health. Our vision is to build the leading longevity-based skin health company and create products grounded in rigorous science that help people maintain healthier skin as they age,' commented Saunders.

“我们仍处于理解长寿科学如何变革人类健康的早期阶段。我们的愿景是打造领先的以长寿为核心的皮肤健康公司，并基于严谨的科学研发产品，帮助人们在衰老过程中维持更健康的肌肤。”桑德斯评论道。

The financing follows a significant period of recognition and growth for Rapalogix Health. In 2026, the company earned several industry awards and made strategic additions to its leadership team, in addition to growing its commercial salesforce in support of the Re-Q national launch. Most recently, in conjunction with this funding, Rapalogix appointed Neetu Dhaliwal and Craig Gordon, MD, to its Board of Directors, further strengthening its governance as the company enters its next phase of growth..

此次融资紧随Rapalogix Health获得广泛认可并实现显著增长的重要时期。2026年，公司荣获多项行业奖项，并对领导团队进行了战略性扩充，同时扩大了商业销售团队，以支持Re-Q在全国范围内的上市发布。最近，结合本轮融资，Rapalogix任命Neetu Dhaliwal和Craig Gordon医学博士加入公司董事会，随着公司进入下一个增长阶段，其治理结构得到进一步加强。

About Rapalogix Health

关于 Rapalogix Health

Rapalogix Health is a California-based biotechnology company pioneering the next evolution in skin health. We translate foundational insights in longevity science into transformative dermatological solutions. Grounded in a science-first approach, the company is developing an innovative pipeline of prescription therapeutics and professional skincare products.

Rapalogix Health 是一家总部位于加利福尼亚州的生物技术公司，致力于开创皮肤健康的下一代演进。我们将长寿科学的基础洞察转化为具有变革性的皮肤科解决方案。秉持科学至上的理念，公司正在开发一系列创新的处方疗法和专业护肤产品。

Re-Q Pro-Longevity Face Serum, the first product from Rapalogix's professional skincare brand, Re-Q Health, is now available at dermatology and aesthetic practices in the United States. Re-Q Pro-Longevity Face Serum is powered by RLX-201, Rapalogix's proprietary pro-longevity molecule designed to reset and restore exhausted skin cells, extend their longevity, and deliver healthy and youthful skin over a lifetime..

Re-Q Pro-Longevity 面部精华液是 Rapalogix 旗下专业护肤品牌 Re-Q Health 的首款产品，现已在美国的皮肤科及医美诊所上市。Re-Q Pro-Longevity 面部精华液的核心成分为 RLX-201，这是 Rapalogix 专有的促长寿分子，旨在重置并修复疲惫的皮肤细胞，延长其寿命，从而在全生命周期内维持健康年轻的肌肤状态。

For more information on Rapalogix Health, visit

如需了解更多关于 Rapalogix Health 的信息，请访问

www.rapalogix.com

www.rapalogix.com

and follow Rapalogix on

并在以下平台关注 Rapalogix

LinkedIn

领英

and

和

Instagram

Instagram

.

。

For more information on Re-Q, visit

如需了解更多关于 Re-Q 的信息，请访问

www.reqhealth.com

www.reqhealth.com

and follow Re-Q on

并关注 Re-Q 在

Instagram

Instagram

.

。

About Cambrian Bio

关于寒武纪生物

Cambrian Bio (Cambrian BioPharma Inc.) is a clinical-stage drug development company focused on building therapeutics to treat and prevent today's most debilitating chronic diseases, with programs targeting critical metabolic sensing functions that decline with age, including AMPK and mTOR. To learn more, visit .

Cambrian Bio（Cambrian BioPharma Inc.）是一家处于临床阶段的药物开发公司，专注于打造用于治疗及预防当今最严重慢性疾病的疗法，其研发项目针对随年龄增长而衰退的关键代谢感应功能，包括AMPK和mTOR。欲了解更多信息，请访问。

www.CambrianBio.com

www.CambrianBio.com

and follow us on

并在以下平台关注我们

LinkedIn

领英

and

和

X

X

.

。

About Woodline Partners

关于 Woodline Partners

Woodline Partners implements a fundamental equity investment strategy, represented by a tenured team of global industry specialists. Anchored by corporate partnerships, the firm's research process aims to identify company-specific insights that drive the long-term competitiveness of companies under coverage.

Woodline Partners 实施基本面股票投资策略，由一支经验丰富的全球行业专家团队执行。以企业伙伴关系为基石，公司的研究流程旨在识别能够推动覆盖范围内公司长期竞争力的特定公司洞察。

Woodline manages approximately $22 billion in assets across four global offices..

伍德莱恩在全球四家办事处管理着约220亿美元的资产。

About

关于

GordonMD

戈登医学博士

Global Investments

全球投资

LP

LP

GordonMD Global Investments LP was founded in 2021 by Craig Gordon, MD, a licensed physician with 15+ years of buy-side experience managing global biopharmaceutical portfolios. The firm manages private funds and a public fund, each focused on differentiated investment opportunities in biopharmaceutical companies primarily located in the U.S., Europe and Japan.

GordonMD Global Investments LP 由克雷格·戈登医学博士于2021年创立。戈登博士是一名持有执照的医师，拥有超过15年的买方经验，专注于管理全球生物制药投资组合。该公司管理着多只私募基金和一只公募基金，每只基金均专注于主要位于美国、欧洲和日本的生物制药公司的差异化投资机会。

GordonMD's investment approach combines first-hand medical knowledge with rigorous bottom-up analysis to identify prospective investments with the greatest growth opportunities..

GordonMD 的投资方法将一手医学知识与严谨的自下而上分析相结合，以识别具有最大增长潜力的潜在投资标的。

SOURCE Rapalogix Health, Inc.

来源：Rapalogix Health, Inc.

21

二十一

%

%

more press release views with

更多新闻稿浏览量

Request a Demo

申请演示